A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

Craig C. Hofmeister, Nita Williams, Susan Geyer, Erinn M. Hade, Mindy A. Bowers, Christian T. Earl, John Vaughn, Anissa Bingman, Kristina Humphries, Gerard Lozanski, Robert A. Baiocchi, Samantha M. Jaglowski, Kristie Blum, Pierluigi Porcu, Joseph Flynn, Sam Penza, Don M. Benson, Leslie A. Andritsos, Steven M. Devine

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Abstract Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11-cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (> 0.35 μg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy.

Original languageEnglish (US)
Pages (from-to)1043-1049
Number of pages7
JournalLeukemia and Lymphoma
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2015

Keywords

  • Chemotherapeutic approaches
  • Lymphoma and Hodgkin disease
  • Vaccines

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma'. Together they form a unique fingerprint.

Cite this